
|Articles|November 13, 2014
- NSCLC (Issue 5)
- Volume 5
- Issue 1
The Future of Squamous Cell Lung Cancer Treatment
Author(s)Peter Hammerman, MD, PhD
Peter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Advertisement
Peter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Learn more about the treatment of squamous cell lung cancer > >
Articles in this issue
about 11 years ago
Veliparib Shows Potential in Squamous Cell NSCLCabout 11 years ago
IDO Inhibitors May Augment Immunotherapy in NSCLCabout 11 years ago
Multidisciplinary Teams in NSCLC Important for Optimal Patient Careabout 11 years ago
The Role of Chemotherapy in the Treatment of Lung Cancerabout 11 years ago
The Challenges of Treating Lung Cancerabout 11 years ago
Early Detection and Molecular Testing Evolving for NSCLCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5


















